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Pseudomonas aeruginosa is an opportunistic human pathogen and one of the leading causes of nosocomial
infections worldwide. The difficulty in treatment of pseudomonas infections arises from being multidrug
resistant (MDR) and exhibits resistance to most antimicrobial agents due to the expression of different
mechanisms overcoming their effects. Of these resistance mechanisms, the active efflux pumps in
Pseudomonas aeruginosa that belong to the resistance nodulation division (RND) plays a very important
role in extruding the antibiotics outside the bacterial cells providing a protective means against their
antibacterial activity. Beside its role against the antimicrobial agents, these pumps can extrude biocides,
detergents, and other metabolic inhibitors. It is clear that efflux pumps can be targets for new antimicrobial
agents. Peptidomimetic compounds such as phenylalanine arginyl b-naphthylamide (PAbN) have been
introduced as efflux pump inhibitors (EPIs); their mechanism of action is through competitive inhibition with
antibiotics on the efflux pump resulting in increased intracellular concentration of antibiotic, hence, restoring
its antibacterial activity. The advantage of EPIs is the difficulty to develop bacterial resistance against them,
but the disadvantage is their toxic property hindering their clinical application. The structure activity
relationship of these compounds showed other derivatives from PAbN that are higher in their activity with
higher solubility in biological fluids and decreased toxicity level. This raises further questions on how can we
compact Pseudomonas infections. Of particular importance, the recent resurgence in the use of older
antibiotics such as polymyxins and probably applying stricter control measures in order to prevent their
spread in clinical sittings.
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P
seudomonas aeruginosa is one of the most pre-
valent nosocomial pathogens associated with
higher mortality rates and antibiotic costs. It can
survive in different environments including soil, plants,
and animals. It is also considered the most opportunistic
human pathogen especially in immunocompromised
patients and one of the top five pathogens of nosocomial
diseases worldwide (1).
Pseudomonas infections are commonly reported in
burns, urinary tract infections (UTI), and pulmonary
diseases such as cystic fibrosis (CF). This diversity of
pseudomonas infections is due to the development of
various adaptive mechanisms such as the nutritional and
metabolic pathways besides the regulation of gene ex-
pression. In addition, its ability to form biofilms provides
greater protection against host immune defense systems
and the susceptibility to various antimicrobial agents (2).
Pseudomonas aeruginosa is a multidrug resistant organ-
ism (MDR) and considered a phenomenon of bacterial
resistance. This is demonstrated by different types of
antibiotic resistance that are presented by this organism
such as derepression of chromosomal AmpC cephalos-
porinase, production of plasmid or integron mediated
b-lactamases from different molecular classes, lowerouter
membrane permeability (loss of OprD proteins), over-
expression of active efflux systems, synthesis of amino-
glycoside modifying enzymes (phosphoryl transferases,
acetyl transferases, and adenyl transferases), and struc-
tural alterations of topoisomerases II and IV determining
quinolone resistance. Taking into consideration that all
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thereby conferring multiresistant phenotypes (36).
Quinolones (fluoroquinolones) and aminoglycosides
are the major classes of antibiotics used in the treatment
of infections caused by Pseudomonas aeruginosa. Fluor-
oquinolones act by inhibition of DNA replication and
transcription via inhibition of DNA gyrase and topoi-
somerase IV. The mode of action of aminoglycosides
depends on the inhibition of protein synthesis by binding
to the 30s ribosomal subunit resulting in misreading of
mRNA by inhibition of the transfer of peptidyl-tRNA
across the ribosome (7). Even the use of antibiotic
combinations between b-lactams antibiotics or b-lactams
with b-lactamase inhibitors or different classes of ami-
noglycosides is useless in the management of pseudomo-
nas infections (8). This has directed the attention to novel
antimicrobial agents such as antibodies, phages, selective
peptides, novel b-lactams, or other combinations of novel
b-lactamase inhibitors with known penicillins or cepha-
losporins (8).
Role of efflux pumps in antibiotic resistance
Efflux pumps contribute to multidrug resistance as they
expel different types of antibiotics and chemicals such as
dyes, organic solvents, detergents, molecules needed for
the cellcell communication, biocides, and metabolic
products. Hence understanding the mechanisms by which
these pumps act and how to overcome its activity opens
the door for restoring the antibiotic activity and con-
stitute a promising target for novel antibacterial agents
(913).
The bacterial multidrug efflux transporters can be
divided into five classes: (1) small multidrug resistance
(SMR), (2) major facilitator superfamily (MFS), (3)
resistance nodulation cell division (RND), (4) multidrug
and toxic compound extrusion (MATE), (5) ATP-binding
cassette (ABC). Those five classes obtain energy required
for the active transporting either from H protons
(RND, SMR, and MFS), Na dependant (MATE), or
by hydrolysis ATP (ABC) (12, 14).
The efflux pump transporter in Pseudomonas
aeruginosa belongs to the (RND) family. It is composed
of three parts, the transporter, the linker, and the outer
membrane pore that ensures that the extruded compound
doesnotremainintheperiplasm,hence,avoidingitsreturn
to the cytosol (15). There are 12 types of RND efflux
systems including for example MexAB-OprM, MexCD-
OprJ, MexEF-OprN, MexXY-OprM, MexPQ-OpmE,
MexMN-OprM, and MexVW-OprM that differ in their
substrates as shown in Table 1. Of these different types of
efflux pumps, MexAB-OprM is the one constitutionally
expressed in Pseudomonas aeruginosa accounting for the
intrinsic resistance to flouroquinolones and pathogenicity
of this organism (13, 1619). As shown in Fig. 1 MexAB-
OprM consists of three subunits, MexA and OprM acting
by substrate recognizing energy transfer and connecting
the MexB and OprM, and the antibiotic discharge duct
protein (20). As a result, antibiotics are entrapped by
MexB and transferred to OprM and finally extruded by
MexA (2123). Higher resistance profiles of Pseudomonas
aeruginosa to quinolones can result from mutations in
the genes encoding for efflux pump MexAB-oprM that
regulate the resistance for quinolones, b-lactams, and
b-lactamaseinhibitors(24).Besideitswell-definedactivity
against the known antimicrobial agents, MexAB-OprM
pump confers resistance to the other non-antibiotic
compounds such as tea tree oil and its monoterpene
components a-terpineol and the related alcohols (25).
In spite of being important to provide resistance to
many antibiotics, MexAB-OprM pump cannot confer
resistance to the human antimicrobial polypeptides
cathelicidins, a and b-defensins by testing the action of
these antimicrobial agents versus the wild-type pseudo-
monas strains and strains mutant in the genes encoding
for the pump expression (26). On the other hand, it was
shown that MexXY-OprM has a role in the resistance to
Table 1. Substrates and the general regulators of major efﬂux pumps in Pseudomonas aeruginosa
Efflux pump Substrates Regulators and function Reference
MexAB-OprM b-lactam, b-lactam inhibitors, SDS, fluoroquinolones, tetracycline,
novobiocin, chloramphenicol, macrolides, trimethoprim, triclosan,
ethidium bromide, aromatic hydrocarbons, thiolactomycin, cerulenin,
acylated homoserine lactones.
MexR (repressor) (54, 58)
MexCD-OprJ b-lactam, fluoroquinolones, tetracycline, chloramphenicol, novobiocin,
macrolides, trimethoprim, triclosan, ethidium bromide, SDS, aromatic
hydrocarbons, crystal violet, acriflavin.
NfxB (repressor) (54)
MexEF-OprN Fluoroquinolones, chloramphenicol, trimethoprim, triclosan, aromatic




MexGHI-OprD Vanadium, acylated homoserine lactones? LasR? RhlR? (unknown) (19)
MexXY Tetracycline, erythromycin, aminoglycosides, fluoroquinolones MexZ (repressor) (14)
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deletion of the genes responsible for this efflux pump
expression resulting in the increased sensitivity of the
mutant strains to aminoglycosides than the wild-type
strains (27).
Role of efflux pumps to antibiotic resistance in
biofilms
It is well known that biofilms can play an important role
in resistance to antibiotics due to the extracellular
polysaccharide matrix, higher bacterial cell density, and
lower bacterial growth that provide a good protective
means for the bacterial cells against antimicrobial agents
(28). In addition, a novel efflux pump has been identified
as important to increase the bacterial antibiotic resistance
in biofilms rather than the planktonic cells where
the deletion of the genes encoding for this pump render
the cells in biofilms more sensitive to antibiotics, such
as tobramycin, indicating that this efflux pump is essen-
tial to pseudomonas antibiotic resistance in biofilms
rather than the planktonic state (29).
Genetic organization of Pseudomonas
aeruginosa RND efflux operons
The genetic organization of RND efflux pump operons
comprises of three steps. First, the genes regulating the
RND transporter and membrane fusion protein are
always present. Second, the genes encoding the operon
regulators and the outer membrane channel proteins
are not always present taking into account that some
operons do not have regulatory genes or outer membrane
regulatory gene linked to the efflux operon. Third,
some additional regulatory genes can be present beside
the regulatory genes for the efflux transporter and
membrane fusion protein such as in case of mexGHI-
opmD that contains mexG, which encodes a membrane
protein required for pump function (30).
Regulation of expression of Pseudomonas
aeruginosa RND efflux pumps
Efflux systems other than MexAB-OprM are tightly
regulated that recently was verified by transcriptional
profiling using Affymetrix Gene Chips. This expression
differs from one system to the other, where the expression
of MexGHI-OprM is dependent on the cell density
indicating that its regulator is the quorum signaling
(26), while in the case of MexXY its expression is
inducible and enhanced by the presence of certain
antibiotics (31). The CzrAB-OpmN divalent cation
RND pump is regulated via two compartment regulatory
systems in the presence of divalent cations and some
isolates that resist antibiotic treatment show susceptibility
to the same antibiotic when propagated in the laboratory
suggesting inducible components of resistance (13). Other
efflux systems are overexpressed as a result of mutations
in their encoding genes for regulatory proteins due to the
exposure antimicrobial agents either in vivo or in vitro
taking into consideration that these mutations are
persistent, which is indicated by the expression that
remains long even after removal of the selective pressure
(32). For MexAB-OprM, which is always expressed
in low but detectable amounts, Hao et al. (33) have
shown that MexR, which is a MarR family protein,
can negatively regulate multidrug efflux systems in
Pseudomonas aeruginosa. The mechanism of MexR-
regulated antibiotic resistance is due to the formation
of intermonomer disulfide bonds in MexR dimer that
leads to its dissociation from promoter DNA, derepres-
sion of the mexAB-oprM drug efflux operon, and increa-










Fig. 1. Schematic illustration of the main efﬂux pump
MexAB-OprM in Pesudomonas aeuroginosa as examples
for the Resistance-Nodulation-Division (RND) family
showing that it is energy dependant on hydrogen protons.
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regulate the gene expression of MexAB-OprM, where
azithromycin lowers the expression of this efflux pump by
70% resulting in the increased sensitivity of Pseudomonas
aeuroginosa to different antibiotics such as chloramphe-
nicol and tetracycline. Besides the previously known
regulators, there are other unidentified regulators since
many efflux systems are expressed in the absence of their
regulatory factors (34, 35). Eisaku et al. (36) have shown
that the OprM subunit of efflux pump MexAB-OprM
can be replaced by the OprN subunit in MexEF-OprN
without affecting its activity but the reverse is not.
The efflux pump inhibitors as new
therapeutic agents
The continuous increase in the development of multidrug
resistance by many pathogens has resulted in difficulties
fighting many infectious diseases. In view of the fact that
the majority of those multidrug resistant pathogens
expresses and overproduces efflux pumps that are re-
sponsible for the expelling and extruding of the anti-
biotics from inside the cells, the new direction for other
chemotherapeutics is the use of efflux pump inhibitors
(EPIs) (37). Using the (EPIs) together with antibiotics
can reduce the invasiveness of Pseudomonas aeruginosa
besides its role in lowering the antibiotic minimal
inhibitory concentration (18). For example, the sensitivity
to ciprofloxacin by Pseudomonas aeruginosa is largely
increased upon using this inhibitor proving that efflux
pumps play a role in the resistance of this organism to
this antibiotic (38). Thus the inhibition of the efflux
pumps is promising in order to (1) increase the intracel-
lular drug concentration, (2) restore the drug activity
against the resistant strains, and (3) minimizes further
development of resistant strains. However, this requires
the understanding of the structural and physiological
mechanisms of the responsible efflux pumps (29, 39).
The inhibition of efflux pumps can be achieved by
different mechanisms as shown in (Fig. 2): (1) interfer-
ence with the regulatory steps needed for the expression
of the efflux pump, (2) chemical changes in the antibiotic
structure hence hindering its attachment as the specific
substrate, (3) disruption of the assembly of the efflux
pump-components, (4) inhibition of the substrate (anti-
biotic) binding by either competitive or non-competitive













5-Blocking outer membrane channel
1-Interference with the regulatory steps
Fig. 2. Schematic illustration showing the general mechanisms of efﬂux pump inhibition and the targets that can be affected
using efﬂux pump MexAB-OprM efﬂux pump as an example.
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compound, (6) interference with the energy required for
the pump activity (37, 40).
Many compounds were tested for their efflux pump
inhibition ability including some analogues for antibiotic
substrates and other chemical compounds, but few are
used that take into consideration the structure-activity
relationship and the spectrum of the activity (39). The
general methodology used for testing the efficacy of
these efflux inhibitors is simply performed by compar-
ing the intracellular concentration of the added antibiotic
tothebacterial cell culturebefore and after the additionof
the (EPIs) such as phenylalanine arginyl b-naphthylamide
(PAbN). If the compound under testing showed higher
intracellular concentration of the antibiotic, it is consid-
ered a good efflux inhibitor and vice versa (41, 42).
Peptidomimetic compounds (PAbN) as efflux
inhibitors against pseudomonas infections
The most widely used compounds as (EPIs) for pseudo-
monas overexpressing MexAB pump are the group of
peptidomimetic molecules with phenylalanine arginyl
b-naphthylamide (PAbN) as a leading compound
(MC-207,110) (Fig. 3a) and other many derivatives being
studied using the structure activity relationship. The
mechanism of action of these inhibitors is through
competitive inhibition mechanism, where the efflux
pumps recognize them as a substrate instead of the target
antibiotics (quinolones mainly ciprofloxacin and levo-
floxacin) and as long as the pumps expel these inhibitors
outside the cells, the antibiotic remains intracellular and
increasing in concentration. Taking into consideration
that PAbN has a differential behavior, meaning that it
can compete with certain antibiotics and not the other
depending on the nature of the efflux pump and the large
substrate-binding site (4345).
It was also shown that PAbN can restore the activity of
other unrelated antibiotics such as chloramphenicol and
macrolides; hence, it can be considered a broad spectrum
efflux pump inhibitor (43, 46). Other derivatives were
designed from PAbN such as MC-04,124 (Fig. 3a), which
is more stable in biological fluids, shows less toxicity
levels and more activity against Pseudomonas aeruginosa
overexpressing efflux pumps (47).
Structure-activity relationship of
peptidomimetic compounds
The structural activity relationship of these compounds
revealed that the modification of these compounds by the
addition of various hydrophilic chains had yielded a
pyridopyrimidine compound (Fig. 3b) with improved
solubility (e.g. morpholine derivative) that showed higher
activity through the potentiation of flouroquinolones
and b-lactam antibiotics in addition to inhibition of the
b-lactam efflux (17, 48, 49).
The PAbN-derived (EPIs) still remain the most studied
and developed family against Pseudomonas aeruginosa,
though more studies concerning the structure activity
relationship, pharmacokinetics, and stability in biological
fluids are required. The main advantage of using the
PAbN-derived (EPIs) is the difficulty to develop resis-
tance to them, where any pump mutation leading to
(a) 
(b) 
Fig. 3. Efﬂux pump inhibitors (EPIs) acting against Pseudomonas aeruginosa (a) phenylalanine arginyl b-naphthylamide, PAbN
(MC-207,110) and its derivative (MC-04,124) and (b) pyridopyrimidine derivative.
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substrate. The disadvantage of those compounds is their
low affinity to the target that necessitates the use of
higher doses and for a longer time in addition to only
substrates that share the inhibitor binding site will be
affected (40).
The main drawbacks associated with these EPI com-
pounds is their toxic properties hindering their clinical
applications; however, they are used in order to evaluate
the different efflux mechanisms expressed by different
pathogenic bacteria besides the measurement of the
affinity of efflux pumps to them in relation to the
antibiotics (46, 50). It has been demonstrated that
PAbN is more potent as an efflux inhibitor against
MexAB-OprM pump of Pseudomonas aeruginosa when
compared to quinoline derivatives (another class of EPIs)
that could be attributed to the difference in the screening
protocols for the antibiotic used as a substrate (levoflox-
acin versus chloramphenicol) for the two EPI classes
(peptidomimetics or quinoline derivatives) (41).
The Mpex Company has already developed a com-
pound that is a combination of an antibiotic and EPI for
the systemic treatment of serious hospital acquired
infections caused by multidrug resistant pathogens such
as Pseudomonas aeruginosa (37).
Is there a role for older antimicrobials and infection
control measures?
The discovery of polymyxins goes back to 1947 as
products being synthesized from Bacillus polymyxa (51).
There use has declined in the late 19701980s because of
their neuro- and nephrotoxicity and emergence of newer
less toxic antimicrobials (52). However, as many multi-
drug-resistant bacteria including pseudomonas are still
only susceptible to polymyxins (polymyxin B and colistin
[polymyxin E]), this has leading clinicians reconsidering
their application for the management of multidrug-
resistant gram-negative bacterial infections in clinical
practice. In a number of recent studies, it has been
demonstrated that polymyxins remain active against most
gram-negative bacteria in vitro, and that intravenous or
inhaled polymyxins have been found to be effective and
considerably less toxic than reported in older studies (52,
53). For instance, the global resistance rate against
polymyxin B in different centers in Europe, Asia, and
America were 1.3% for P. aeruginosa and 2.1% for
A. baumannii isolates (54). Colistin is available commer-
cially as colistin sulfate (i.e. colistin) and sodium colistin
methanesulfonate (CMS), which is administered parent-
erally. The CMS is an inactive prodrug of colistin and,
after parenteral administration, colistin is formed in vivo
(55, 56).
On the other hand, as cross-contamination appears to
be a common route for the spread of infection by MDR
resistant pseudomonas spp. among patients, there is a
need to underscore the importance of stricter control
measures with recommended infection control practices
to limit the spread of MDR pseudomonas clones inside
the hospital environment (57, 58).
Conclusions
Pseudomonas aeruginosa is responsible for a high percen-
tage of nosocomial infections. The difficulty in its
treatment by antibiotics arises from its capability of
nearly expressing all mechanisms of antibiotic resistance;
hence, it is considered a multidrug-resistant (MDR)
organism (15).
Many compounds have been identified as (EPIs) when
used as adjuvants or in combination with the effective
antibiotics (37). It is also important to take into account
both the pharmacokinetics and pharmacodynamics when
choosing the efflux inhibitors to be adapted with those
combined antibiotics (59). In addition, more assay
techniques are required in order to design and quantify
the (EPIs) and measuring their kinetic parameters in
relation to the efflux pump components. These para-
meters are essential for choosing between the general EPI
that can inhibit the action of one transporter that expels
various antibiotics in one bacterial species or a specific
EPI that inhibits the pumping of one antibiotic family in
various bacteria (39).
In this review it was demonstrated that efflux pumps
are very important to provide resistance to antimicrobial
agents especially in Pseudomonas aeruginosa, hence they
can be targets for new promising antimicrobial com-
pounds. The benefits of these (EPIs) will be the ability to
reuse the traditional antibiotics that became no longer
effective due to the development of bacterial resistance
through the efflux pumps; hence, this will save a lot of
cost and effort that is required to develop new antimi-
crobial agents, which will face the same problem of
developing microbial resistance in the case that these
pumps are not inhibited. Many studies showed that
the use of peptidomimetic molecules as phenylalanine
arginyl b-naphthylamide (PAbN) or other derivatives
of PAbN by structural modifications results in a sig-
nificant decrease of Pseudomonas aeruginosa resistant to
antibiotics  mainly flouroquinolones. In the future more
derivatives are needed using the structure activity rela-
tionship in order to minimize the disadvantages of the
present compounds associated with higher toxic proper-
ties and less biological stability. Also more advanced
techniques for assaying the (EPIs) and determination
of the exact efflux system for each antibiotic are required
in order to design appropriate inhibitors for antibiotics.
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